Atezolizumab Plus Bevacizumab in First Line NSCLC Patients
NCT03836066
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
41
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
Atezolizumab-Bevacizumab
Sponsor
Fundación GECP